The Italian billionaire, who is Walgreens CEO and biggest individual shareholder, has long said he prefers partnerships rather than a large transformative acquisition. But Walgreens hasn’t made a sizable acquisition since its $4.4 billion purchase of more than 1,900 Rite Aids and Wall Street appears to be getting restless. After being pressed on Walgreens quarterly earnings call by the noted J.P. Morgan analyst Lisa Gill, Pessina revealed the drugstore chain was reviewing some targets. "We are constantly reviewing a certain number of companies," Pessina said on a longer-than-usual 90-minute call Tuesday to discuss earnings. But also if you don't have a compatible teams at the end, the merger will not work and you will not be able to deliver synergies."

Source: Forbes April 04, 2019 12:45 UTC